Sanofi (SNY) News Today $51.64 +2.12 (+4.28%) Closing price 04:00 PM EasternExtended Trading$51.30 -0.34 (-0.66%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Sanofi Up Today?Toggle Visibility of Why Is Sanofi Up Today?Sanofi (SNY) is trading higher after reporting third-quarter results that beat consensus, driven by blockbuster Dupixent sales and momentum from newer drug launches. Investors are reacting to strong growth in key products even as vaccines and some legacy businesses lag and overall revenue was down year-over-year. Positive Sentiment: Q3 beat driven by Dupixent and new launches — Sanofi reported EPS above estimates and management highlighted Dupixent surging (now in the multi‑billion euro/dollar range) plus strong contribution from recent launches, which lifted net sales ~7% and boosted margins. Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged Positive Sentiment: Dupixent sales near record levels — Third‑quarter Dupixent sales approached $4–5B (reports vary by source), making it the primary growth engine offsetting vaccine declines and underpinning the stock move. Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline Positive Sentiment: Analyst commentary highlights pipeline upside — Equity research and street notes point to promising Ventyx clinical data and favorable analyst reaction, which supports upside expectations beyond the quarter. Ventyx ‘unequivocally impressive data’ should spur Sanofi, says Clear Street Neutral Sentiment: Guidance unchanged — Management beat near‑term estimates but left the company forecast largely unchanged, so the beat reflects execution rather than a raised outlook. Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged Neutral Sentiment: Operational initiatives — Sanofi expanded its long‑term Medidata collaboration to speed trials and improve patient data, a strategic positive for R&D efficiency but with gradual impact. Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey Negative Sentiment: Top-line headwinds and segment weakness — Revenue was down ~7–7.5% YoY and vaccines faced "negative buzz"/weakness, meaning the beat relied on product mix and margins rather than broad organic growth. Sanofi earnings details and transcript Negative Sentiment: Minor insider selling disclosed — A small sale by Rep. Lisa McClain was reported; amount disclosed is modest and unlikely to drive material moves but is a negative data point for some investors. Rep. Lisa C. McClain Sells Off Shares of Sanofi (NASDAQ:SNY) Posted 4h agoAI Generated. May Contain Errors. SNY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Sanofi 2025 Q3 - Results - Earnings Call PresentationOctober 24 at 1:32 PM | seekingalpha.comStock market today: Dow, S&P 500, Nasdaq futures climb after cooler-than-expected CPI inflation reportOctober 24 at 9:10 AM | finance.yahoo.comSanofi profits beat forecasts despite 'negative buzz' around vaccinesOctober 24 at 9:10 AM | finance.yahoo.comSanofi Jumps As Third-Quarter Dupixent Sales Near $5 BillionOctober 24 at 9:10 AM | msn.comSanofi higher after Q3 beat driven by Regeneron-partnered DupixentOctober 24 at 9:10 AM | msn.comRep. Lisa C. McClain Sells Off Shares of Sanofi (NASDAQ:SNY)October 24 at 8:05 AM | marketbeat.comSanofi $SNY Shares Sold by Ethic Inc.October 24 at 5:47 AM | marketbeat.comSanofi Earnings Driven by New Medicine Sales, Dupixent PerformanceOctober 24 at 2:55 AM | wsj.comSanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchangedOctober 24 at 2:35 AM | reuters.comVentyx ‘unequivocally impressive data’ should spur Sanofi, says Clear StreetOctober 23 at 5:22 PM | msn.comForum Financial Management LP Trims Holdings in Sanofi $SNYOctober 23 at 7:23 AM | marketbeat.comSanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient JourneyOctober 23 at 2:00 AM | globenewswire.comSanofi $SNY Shares Sold by Atria Wealth Solutions Inc.October 22 at 3:36 AM | marketbeat.comPress Release: Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 studyOctober 22 at 2:00 AM | globenewswire.comPress Release: Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot programOctober 20, 2025 | globenewswire.comFLC Capital Advisors Buys New Holdings in Sanofi $SNYOctober 20, 2025 | marketbeat.comPress Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumorsOctober 20, 2025 | globenewswire.comPress Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumorsOctober 20, 2025 | globenewswire.comPress Release: Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-doseOctober 20, 2025 | globenewswire.comCrux Wealth Advisors Has $861,000 Stock Position in Sanofi $SNYOctober 19, 2025 | marketbeat.comBurford Brothers Inc. Acquires Shares of 16,914 Sanofi $SNYOctober 19, 2025 | marketbeat.comTD Asset Management Inc Lowers Stock Holdings in Sanofi $SNYOctober 19, 2025 | marketbeat.comArista Wealth Management LLC Acquires Shares of 7,890 Sanofi $SNYOctober 18, 2025 | marketbeat.comPress Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaOctober 17, 2025 | globenewswire.comPress Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host diseaseOctober 17, 2025 | globenewswire.comYousif Capital Management LLC Buys 6,789 Shares of Sanofi $SNYOctober 17, 2025 | marketbeat.comSanofi (SNY) to Release Earnings on FridayOctober 17, 2025 | marketbeat.comEVOQ Therapeutics Announces Collaboration and License Agreement with SanofiOctober 16, 2025 | prnewswire.comSanofi $SNY Position Lessened by Envestnet Portfolio Solutions Inc.October 16, 2025 | marketbeat.comSanofi $SNY Stock Position Lifted by Aberdeen Group plcOctober 15, 2025 | marketbeat.comSanofi $SNY Shares Sold by US Bancorp DEOctober 14, 2025 | marketbeat.comITM Appoints Annette Breunig as Chief People OfficerOctober 13, 2025 | globenewswire.comZacks Research Has Pessimistic View of Sanofi Q1 EarningsOctober 13, 2025 | marketbeat.comFY2025 EPS Estimates for Sanofi Lifted by Leerink PartnrsOctober 11, 2025 | marketbeat.comLeerink Partnrs Issues Negative Forecast for Sanofi EarningsOctober 10, 2025 | marketbeat.comCallan Family Office LLC Boosts Stock Holdings in Sanofi $SNYOctober 10, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Earns "Hold (C)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comSanofi price target lowered to EUR 101 from EUR 104 at GuggenheimOctober 8, 2025 | msn.comSanofi and Orano Med succeed in mid-stage trial for neuroendocrine tumor therapyOctober 8, 2025 | msn.comBenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND PlatformOctober 8, 2025 | businesswire.comOLD National Bancorp IN Decreases Stock Position in Sanofi $SNYOctober 8, 2025 | marketbeat.comPress Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumorsOctober 8, 2025 | globenewswire.comNovavax’s Nuvaxovid EU approval triggers $25M milestone payment from SanofiOctober 7, 2025 | msn.comNovavax hands over Nuvaxovid marketing rights to Sanofi in the EUOctober 7, 2025 | msn.comMerit Financial Group LLC Has $4.37 Million Stock Holdings in Sanofi $SNYOctober 7, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Given Average Rating of "Buy" by BrokeragesOctober 7, 2025 | marketbeat.comDAVENPORT & Co LLC Has $101.77 Million Stock Holdings in Sanofi $SNYOctober 6, 2025 | marketbeat.comSanofi (SNY) Invests $625 Million in Sanofi VenturesOctober 5, 2025 | msn.comUBS Reaffirms Their Buy Rating on Sanofi (SNYNF)October 4, 2025 | theglobeandmail.comHilltop National Bank Makes New $662,000 Investment in Sanofi $SNYOctober 4, 2025 | marketbeat.com Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNY Media Mentions By Week SNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNY News Sentiment▼0.850.64▲Average Medical News Sentiment SNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNY Articles This Week▼2523▲SNY Articles Average Week Get the Latest News and Ratings for SNY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sanofi and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NVS News AZN News NVO News GSK News ARGX News TAK News INSM News ONC News BNTX News TEVA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNY) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.